Login to Your Account

Clinic Roundup

Wednesday, April 18, 2012
• Idera Pharmaceuticals Inc., of Cambridge, Mass., said it treated the first patient in a Phase II trial of IMO-3100, its lead Toll-like receptor (TLR) 7 and TLR9 inhibitor, in moderate to severe plaque psoriasis. The study is designed to enroll 45 patients randomized to receive IMO-3100 at one of two doses or placebo, administered by subcutaneous injection once weekly for four weeks.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription